{
    "topic": "coronavirus",
    "source": "New York Post (News)",
    "bias": 2,
    "url": "https://nypost.com/2020/07/01/us-buys-nearly-all-global-stock-of-coronavirus-drug-remdesivir/",
    "title": "US buys nearly all global stock of coronavirus drug remdesivir",
    "date": "2020-07-01",
    "authors": "",
    "content": "The US has bought almost the entire global supply of remdesivir , the anti-viral drug that can speed the recovery of patients infected with the coronavirus .\nHealth and Human Services Secretary Alex Azar announced earlier this week an agreement to secure large quantities of the medication from Gilead Sciences until September , allowing US hospitals to buy it .\n\u201c President Trump has struck an amazing deal to ensure Americans have access to the first authorized therapeutic for COVID-19 , \u201d Azar said in a statement .\n\u201c To the extent possible , we want to ensure that any American patient who needs remdesivir can get it . The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people . \u201d\nHHS said it secured more than 500,000 treatment courses of the drug .\n\u201c This represents 100 percent of Gilead \u2019 s projected production for July ( 94,200 treatment courses ) , 90 percent of production in August ( 174,900 treatment courses ) , and 90 percent of production in September ( 232,800 treatment courses ) , in addition to an allocation for clinical trials , \u201d it said .\nRemdesivir will cost $ 3,120 for the typical patient with private health insurance , the drugmaker said Monday , adding that it will cost hospitals about $ 520 per dose for privately insured patients .\nThe shorter , more common course of treatment would work out to $ 3,120 , while the longer duration would cost $ 5,720 , the Wall Street Journal reported .\nThe anti-viral drug is the only one approved by the European Medicines Agency to treat coronavirus patients , according to Euronews .\nAnother drug found to have an effect on coronavirus patients is the steroid dexamethasone , which reduces the number of deaths in the most severely ill patients by up to a third , the news outlet reported , citing British researchers .\n\u201c They \u2019 ve got access to most of the drug supply [ of remdesivir ] , so there \u2019 s nothing for Europe , \u201d Dr. Andrew Hill , senior visiting research fellow at Liverpool University , told the UK \u2019 s Guardian .\n\u201c This is the first major approved drug , and where is the mechanism for access ? Once again we \u2019 re at the back of the queue , \u201d he said .\nHill added the UK could still get its hands on remdesivir through what is known as a compulsory license , which overrides the intellectual property rights of the company .\nThat would allow the UK to purchase from generic companies in Bangladesh or India , where Gilead \u2019 s patent is not recognized , the Guardian reported .",
    "content_original": "Sign up for our special edition newsletter to get a daily update on the coronavirus pandemic.\n\nThe US has bought almost the entire global supply of remdesivir, the anti-viral drug that can speed the recovery of patients infected with the coronavirus.\n\nHealth and Human Services Secretary Alex Azar announced earlier this week an agreement to secure large quantities of the medication from Gilead Sciences until September, allowing US hospitals to buy it.\n\n\u201cPresident Trump has struck an amazing deal to ensure Americans have access to the first authorized therapeutic for COVID-19,\u201d Azar said in a statement.\n\n\u201cTo the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people.\u201d\n\nHHS said it secured more than 500,000 treatment courses of the drug.\n\n\u201cThis represents 100 percent of Gilead\u2019s projected production for July (94,200 treatment courses), 90 percent of production in August (174,900 treatment courses), and 90 percent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials,\u201d it said.\n\nRemdesivir will cost $3,120 for the typical patient with private health insurance, the drugmaker said Monday, adding that it will cost hospitals about $520 per dose for privately insured patients.\n\nThe shorter, more common course of treatment would work out to $3,120, while the longer duration would cost $5,720, the Wall Street Journal reported.\n\nThe anti-viral drug is the only one approved by the European Medicines Agency to treat coronavirus patients, according to Euronews.\n\nAnother drug found to have an effect on coronavirus patients is the steroid dexamethasone, which reduces the number of deaths in the most severely ill patients by up to a third, the news outlet reported, citing British researchers.\n\n\u201cThey\u2019ve got access to most of the drug supply [of remdesivir], so there\u2019s nothing for Europe,\u201d Dr. Andrew Hill, senior visiting research fellow at Liverpool University, told the UK\u2019s Guardian.\n\n\u201cThis is the first major approved drug, and where is the mechanism for access? Once again we\u2019re at the back of the queue,\u201d he said.\n\nHill added the UK could still get its hands on remdesivir through what is known as a compulsory license, which overrides the intellectual property rights of the company.\n\nThat would allow the UK to purchase from generic companies in Bangladesh or India, where Gilead\u2019s patent is not recognized, the Guardian reported.",
    "source_url": "www.nypost.com",
    "bias_text": "right",
    "ID": "fuHSlZH4Pv0mMIRs"
}